Saturday, September 01, 2012 10:05:53 PM
Regarding your cost call outs, consider that your cost of development stats need to place PPHM at the FDA trial design discussion phase, since Phase 2 is wrapping up. PPHM isn't starting from zero here.
Much of that cost you reference for commercialization has already passed the Bavi development track. PPHM managed to leverage Avid as their in house source of trial product and did other things to keep the cost down. If PPHM decides to go it alone, there will need to be trial results reported combined with uncooperative Pharma partner prospects. At this point, PPHM would need maybe $25 million plus operational funding to keep the rest of their business viable to go it alone on Phase 3. yes indeed. PPHM is ready to launch a Bavi Phase 3 trial if the FDA so approves.
One thought that has come to my mind is that those bankers who wrote that loan enabling two $15 million funding tranches might be persuaded to fund a Phase 3 trial in exchange for ???
Best wishes and IMO.
KT
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
